AutovaxID

PDF
Print
E-mail
Written by Administrator
Monday, 21 June 2010 20:40

Biovest has developed the AutovaxID™ bioreactor as an ideal production platform (cGMP compliant) for the scalable manufacture of difficult-to-produce biologics including personalized medicines, monoclonal antibodies, cell culture vaccines and therapeutics targeting highly infectious agents. This system’s multiple advantages and benefits have been proven in the production of Biovest’s autologous anti-lymphoma vaccine (BiovaxID®) targeting B-cell blood cancers, representing how automated hollow fiber technology is integral toward providing a robust and dependable commercial process for the manufacture of personalized cancer vaccines.


Magnified views of cells growing on hollow fibers
The Role of AutovaxID in the Production of BiovaxID Cancer Vaccine
Hollow-Fiber Bioreactor
Cultures Tumor Derived Cells
(Heterohybridoma)
for Id Protein Production
Id Protein
Secreted and
Purified
for BiovaxID
Last Updated ( Tuesday, 01 February 2011 15:40 )

The Future of
Personalized Medicine Production

The future of personalized medicine requires a change in the bio-manufacturing paradigm to specialize in small, patient-specific production batches running in parallel or in a campaign fashion.  As such, the use of a compact, portable, disposable bioreactor is required, such as AutovaxID, rather than traditional large fermentation tanks.

BiovaxID®

Personalized cancer vaccine targeting certain B-cell lymphomas

Patients Organize Petition Drive

Urging for accelerated approval of lymphoma vaccine 

Media Center

Biovest headlines, videos, webcasts and feature articles